Company intelligence / Profile preview

Aclipse Therapeutics

KINGOFPRUSSIA/RADNORPAAREA, PENNSYLVANIA(PA), USA

Ownership: Private
Development stage: Other

Overview

Aclinical-stage biopharmaceutical company developing small-molecule therapeutics targeting severe neuromuscular and gastrointestinal diseases. Lead asset M107 enters US-based Phase II trials as the first potential disease-modifying therapy for gastroparesis; second asset M102 will enter human studies in ALS/MND with a novel dual-pathway mechanism.

Therapeutic areas: GastroenterologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

M102

Preclinical

Partnerships

{"partner": "ChongKunDangPharmaceuticalCorporation(CKD)","details":"Exclusiveworldwidelicense(excludingSouthKorea, Indonesia,Vietnam)todevelopCKD'slobeglitazone(M107)forgastroparesisaswellasotherpotentialindications."}

Beyond the preview

Go deeper on Aclipse Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aclipse Therapeutics.

Explore the full profile